Literature DB >> 2477337

Effects of cyclosporin A and verapamil on the intracellular daunorubicin accumulation in Chinese hamster ovary cells with increasing levels of drug-resistance.

M H Silbermann1, A W Boersma, A L Janssen, R J Scheper, H Herweijer, K Nooter.   

Abstract

Multidrug-resistance (MDR) is characterized by the presence of a 170 kDa glycoprotein (P-glycoprotein) in the plasma membrane. P-glycoprotein is thought to act as an efflux pump, leading to reduced drug accumulation in MDR cells. This defect in drug accumulation can be overcome by membrane transport modulating agents (MTMAs). We determined the concentration of MTMA needed for maximal restoration of daunorubicin content in 4 Chinese hamster ovary cell lines with increasing levels of drug-resistance using flow cytometry. Stimulation of daunorubicin accumulation occurred in a dose-dependent manner. The required level of MTMA needed for maximal drug accumulation increased with the level of drug-resistance. CHrA3 cells, which have a level of resistance comparable to clinical samples, needed relatively low concentrations of MTMA for maximal restoration of drug accumulation. This indicates that, in trial combining drugs and MTMAs, low dosages of MTMAs could be sufficient for optimal potentiation of cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477337     DOI: 10.1002/ijc.2910440428

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype.

Authors:  P A te Boekhorst; J van Kapel; M Schoester; P Sonneveld
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Chemosensitisation of a drug-sensitive parental cell line by low-dose cyclosporin A.

Authors:  P R Twentyman; K A Wright
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Evolutionarily Conserved Roles for Blood-Brain Barrier Xenobiotic Transporters in Endogenous Steroid Partitioning and Behavior.

Authors:  Samantha J Hindle; Roeben N Munji; Elena Dolghih; Garrett Gaskins; Souvinh Orng; Hiroshi Ishimoto; Allison Soung; Michael DeSalvo; Toshihiro Kitamoto; Michael J Keiser; Matthew P Jacobson; Richard Daneman; Roland J Bainton
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

4.  Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour.

Authors:  W Van de Vrie; R L Marquet; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.

Authors:  W Van de Vrie; E E Gheuens; N M Durante; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 6.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

7.  Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.

Authors:  Hong Li; Hyo-Eon Jin; Wooyoung Kim; Yong-Hae Han; Dae-Duk Kim; Suk-Jae Chung; Chang-Koo Shim
Journal:  Pharm Res       Date:  2008-07-25       Impact factor: 4.200

8.  Study on mechanism of low bioavailability of black tea theaflavins by using Caco-2 cell monolayer.

Authors:  Fengfeng Qu; Zeyi Ai; Shuyuan Liu; Haojie Zhang; Yuqiong Chen; Yaomin Wang; Dejiang Ni
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

9.  A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

Authors:  J Verweij; H Herweijer; R Oosterom; M E van der Burg; A S Planting; C Seynaeve; G Stoter; K Nooter
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.